Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Zacks Investment Research to “Hold”

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, November 14th.

According to Zacks, “Regeneron’s third-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea’s sales. Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. The drug was also approved in Europe. The geographic expansion of the drug will further boost sales. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line and reduce the company’s dependence on Eylea for growth. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress payer utilization management restrictions in the United States.”

REGN has been the topic of several other research reports. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Leerink Swann reissued an “outperform” rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Goldman Sachs Group reissued a “neutral” rating and set a $472.00 target price (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Robert W. Baird cut shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price on the stock. in a research note on Tuesday, August 8th. Finally, Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $467.84.

Regeneron Pharmaceuticals (NASDAQ REGN) traded up $11.61 during mid-day trading on Tuesday, hitting $373.47. 1,799,404 shares of the company were exchanged, compared to its average volume of 954,248. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals has a 1-year low of $340.09 and a 1-year high of $543.55. The firm has a market cap of $40,125.25, a PE ratio of 32.34, a PEG ratio of 1.47 and a beta of 1.54.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter last year, the company earned $3.13 EPS. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. analysts expect that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current fiscal year.

In other news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Robert E. Landry sold 663 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total transaction of $330,571.80. Following the completion of the sale, the senior vice president now owns 10,099 shares in the company, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Insiders have sold 4,352 shares of company stock worth $2,037,772 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in REGN. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. increased its position in Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the period. FNY Partners Fund LP increased its position in Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares during the period. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares during the period. Finally, IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 33.2% during the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 96 shares during the period. 69.47% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/regeneron-pharmaceuticals-inc-regn-lifted-to-hold-at-zacks-investment-research/1782631.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle


Leave a Reply

 
© 2006-2017 BBNS.